Abstract
Usually, wherever breast STAT5a is present, PRLR is reduced; without STAT5a PRLR becomes abundant. Five breast lesions essentially lacking both were tested immunohistochemically for PRLR isoforms. The intermediate isoform was essentially only detected in these lesions. In some breast lesions PRLR isoforms may be involved in JAK/STAT pathway disturbances.
Keywords: Breast, STAT5a, PRLR, Immunohistochemistry, Intermediate Isoform
Protein & Peptide Letters
Title: Cells with Minimal Expression of the JAK/STAT Pathway Related Proteins STAT5a and the Prolactin Receptor: Evidence of an Alternate Prolactin Receptor Isoform in Breast Disease
Volume: 17 Issue: 1
Author(s): G. L. Bratthauer, M. D. Stamatakos and T. N. Vinh
Affiliation:
Keywords: Breast, STAT5a, PRLR, Immunohistochemistry, Intermediate Isoform
Abstract: Usually, wherever breast STAT5a is present, PRLR is reduced; without STAT5a PRLR becomes abundant. Five breast lesions essentially lacking both were tested immunohistochemically for PRLR isoforms. The intermediate isoform was essentially only detected in these lesions. In some breast lesions PRLR isoforms may be involved in JAK/STAT pathway disturbances.
Export Options
About this article
Cite this article as:
Bratthauer L. G., Stamatakos D. M. and Vinh N. T., Cells with Minimal Expression of the JAK/STAT Pathway Related Proteins STAT5a and the Prolactin Receptor: Evidence of an Alternate Prolactin Receptor Isoform in Breast Disease, Protein & Peptide Letters 2010; 17 (1) . https://dx.doi.org/10.2174/092986610789909467
DOI https://dx.doi.org/10.2174/092986610789909467 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Microdosing, Imaging Biomarkers and SPECT: A Multi-Sided Tripod to Accelerate Drug Development
Current Pharmaceutical Design Prebiotic Carbohydrates for Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecularly Imprinted Solid Phase Extraction Before Capillary Electrophoresis for the Analysis of Estrogens in Serum Samples
Current Analytical Chemistry Evidence for Complex Binding Profiles and Species Differences at the Translocator Protein (TSPO) (18 kDa)
Current Molecular Medicine Natural Products Triggering Biological Targets- A Review of the Anti-Inflammatory Phytochemicals Targeting the Arachidonic Acid Pathway in Allergy Asthma and Rheumatoid Arthritis
Current Drug Targets Challenges in the Design of Clinically Useful Brain-targeted Drug Nanocarriers
Current Medicinal Chemistry Dendrimer-Curcumin Conjugate: A Water Soluble and Effective Cytotoxic Agent Against Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Patenting Networking and Knowledge Translation in Liposomes for Cancer Therapy
Recent Patents on Nanomedicine Synaptic Plasticity as a Therapeutic Target in the Treatment of Autism-related Single-gene Disorders
Current Pharmaceutical Design TNFα Modulation of Visceral and Spinal Sensory Processing
Current Pharmaceutical Design Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents
Current Cancer Drug Targets Requirements and Perspectives for Integrating Metabolomics with other Omics Data
Current Metabolomics Effects of Drug Transporters on Pharmacological Responses and Safety
Current Drug Metabolism Targeting Ovarian Cancer-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry Pegylated Naloxone in the Treatment of Persistent Opioid-Induced Constipation in Patients with Hematological Malignancies
Cardiovascular & Hematological Agents in Medicinal Chemistry Current κ Opioid Receptor Ligands and Discovery of a New Molecular Scaffold as a κ Opioid Receptor Antagonist Using Pharmacophore-Based Virtual Screening
Current Pharmaceutical Design Continuous Nanostructures for the Controlled Release of Drugs
Current Pharmaceutical Design Signal Transduction Therapy in Pancreatic Cancer
Current Signal Transduction Therapy Synthesis and Neuroprotective Biological Evaluation of Quinazolinone Derivatives via Scaffold Hopping
Current Organic Synthesis Quinones Derived from Plant Secondary Metabolites as Anti-cancer Agents
Anti-Cancer Agents in Medicinal Chemistry